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SUPPLEMENTARY MATERIALS
Combination of copanlisib with cetuximab improves tumor 
response in cetuximab-resistant patient-derived xenografts of 
head and neck cancer
Sequencing analysis
Mutational profiling was performed using an in-
house gene panel targeting 327 genes with the HaloplexHS 
target enrichment system (Agilent, Santa Clara, CA, USA) 
as described previously [1]. Genes had been selected 
based on the results from whole-exome sequencing of 
three independent HNSCC patient cohorts [2, 3] and the 
COSMIC database [4]. The complete coding sequence of 
all exons of the 327 genes was covered, resulting in a target 
region of 1.47 megabase pairs in total. HaloPlexHS library 
preparation was performed using approximately 100 ng of 
DNA (Agilent, protocol version F1, July 2015). Briefly, 
the gDNA was digested and the HaloPlexHS probe library 
was hybridized in the presence of the indexing primer 
cassette and the molecular barcode. The biotinylated DNA-
probe hybrids were captured by magnetic purification of 
the samples with streptavidin-coated magnetic beads. 
Fragmented targets were amplified via PCR at cycling 
conditions recommended by the manufacturer. Subsequent 
to the PCR reaction, the final library was purified using 
AMPure XP magnetic beads (Beckman Coulter, Krefeld, 
Germany). Pooled libraries from patient samples were used 
for paired end (PE) sequencing on the Illumina NextSeq500 
platform with a High Output v2 sequencing kit, 300 cycles 
(Illumina, San Diego, CA, USA), producing 150 bp PE 
reads. A mean read depth of 466-fold (range, 57–2,396) 
was achieved after duplicate removal in the target region.
Sequencing data analysis
Processing of the raw FASTQ files, sequencing 
adaptor trimming, sequence alignment, variant calling and 
duplicate removal was performed with Agilent SureCall 
Software (version 3.5.1.46). For alignment to the human 
reference sequence build 38 (hg19), the BWA-MEM 
algorithm was applied. Variant calling was performed with 
a cut-off of 0.05 for allele frequencies. Genome annotations 
for point mutations and short nucleotide insertions as well 
as deletions were made by using The Cancer-Related 
Analysis of Variants Toolkit (CRAVAT v5.2.4) [5]. Variants 
were filtered based on their functional impact predicted by 
Cancer-Specific High-Throughput Annotation of Somatic 
Mutations (CHASM) [6] and Variant Effect Scoring Tool 
(VEST). Only variants with CHASM and VEST composite 
gene-level P values of < 0.05 were further considered. 
For removal of germline variants, entries with minor 
allele frequencies of > 0.05 reported in exome sequencing 
projects of healthy populations (1000-Genomes; ESP 
v.6500) were excluded from the analysis.
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Supplementary Table 1: Clinical characteristics of patients for PDX models of HNSCC
Tumor ID TNM Stage UICC 7 Grading Age Site of tumor origin Gender Primary/Recurrent HPV status
HN09897 T2N2bM0 IVA G3 58 hypopharynx male recurrent −
HN10110 T2N2cM0 IVA G2 69 oral cavity male primary −
HN10309 T4N2cM0 IVA G3 55 oropharynx male primary +
HN10621 T2N2bM0 IVA G3 61 oropharynx male primary −
HN10632 T2N1M0 III G3 60 oral cavity male primary −
HN10847 T2N1M0 III G2 71 oral cavity female recurrent −
HN10924 T3N2cM0 IVA G2 65 hypopharynx male primary −
HN10960 T2N0M0 II G2 63 oral cavity male primary −
HN10980 T4bN2bM0 IVB G2 59 oral cavity female primary −
HN11097 T4aN2bM0 IVA G2 75 oral cavity female primary −
HN11218 T4N0M0 IVA G2 68 oral cavity female primary −
HN11303 T3N1M0 IVA G2 75 oropharynx male primary +
HN11364 T2N2M0 IVA G2 67 oropharynx male primary +
HN11437 T4bN2cM0 IVB G2 56 oral cavity male primary −
HN11452 T2N0M0 II G2 75 oral cavity male primary −
HN11482 T2N2bM0 IVA G2 61 oral cavity male primary −
HN11527 T2N2bM0 IVA G2 74 oral cavity male primary −
HN11841 T1N0M0 I G2 56 oral cavity female recurrent −
HN11857 T4N2M0 IVA G1 49 oral cavity male primary −
HN13869 T1N2bM0 IVA G1 71 oral cavity male recurrent −
HN14827 T3N2bM0 IVA G2 59 oral cavity female primary −
HN14876 T3N2M0 IVA G2 59 oral cavity female primary −
HN14879 T3N2bM0 IVA G3 57 oral cavity female primary −
HN14965 T3N2bM0 IVA G2 73 oropharynx male primary +
HN14968 T3N0M0 III G3 51 hypopharynx male primary −
HN14976 T4aN2cM0 IVA G2 74 larynx male primary −
HN15046 T4N3M1 IVC G2 61 hypopharynx male primarya −
HN15095 T3N2M0 IVA G2 59 oropharynx female primary −
HN15239 T1N0M0 I G2 26 oral cavity female recurrent −
HN15336 T3N0M0 III G2 54 larynx female recurrent −
HN15348 T4N0M0 IVA G2 54 larynx male recurrent −
HN15399 T4N2cM0 IVA G2 74 oropharynx male primary +
HN15692 T2N2bM0 IVA G2 57 oropharynx male primary +
aprimary metastatic.
Supplementary Table 2: Detected mutations within the PI3KCA gene in the panel of HNSCC PDX 
models










Supplementary Table 3: List of genes included in in-house 327-gene panel
Gene panel
ACACA CDK4 FANCD2 KDR NCOR1 PRKDC SPTBN1
ACTC1 CDKN2A FANCE KEAP1 NCOR2 PRMT5 SRC
ADCY2 CHD1L FANCF KIT NCR1 PROX1 STEAP4
AFF1 CLDN18 FANCG KMT2A NECAB1 PRSS1 STK11
AGTR1 CNTNAP5 FANCI KMT2C NEUROD6 PRUNE2 SULF1
AJUBA COL11A1 FANCL KMT2D NF2 PTEN SYNCRIP
AKAP12 COL1A2 FANCM KRAS NFE2L2 PTPN11 SYNE1
AKT1 CPXCR1 FAT1 KRT14 NOTCH1 PTPRA SYNE2
AKT2 CRABP2 FBXW7 KRT5 NOTCH2 PTPRC SYNE3
ALB CREBBP FCRL4 LAMA1 NOTCH3 PTPRD TARP
ALDH1L1 CSMD3 FGFR1 LAMA2 NPY5R PTPRF TEK
ALK CTCF FGFR2 LAMA3 NRAS PTPRT TERF1
ANKRD30B CTNNB1 FGFR3 LAMA4 NSD1 PTPRZ1 TERF2
ANO1 CUL3 FIGN LAMA5 NTM RAC1 TERT
APC CUX1 FLG LBP NUP214 RAD51C TG
APOB DACH1 FLT3 LCP1 OR2J2 RAP1A TGFBR2
AR DCC FN1 LILRB1 OR2L13 RAP1B THBS1
ARHGAP35 DICER1 FOSL2 LIMK1 OR2M2 RASA1 TLN1
ARID1A DMD FOXO3 LIN28B OR2T12 RB1 TLR4
ASAP1 DNM2 GABRB3 LINGO2 OR4C11 RB1CC1 TP53
ASNS DNMT3A GRID2 LRFN5 OR4M2 RBM5 TP63
ASXL3 DOCK1 GRM1 LRP1 OR52E2 RECQL4 TPO
ATM DOK6 GSTM2 LRP1B OR56A1 REG1A TPP1
ATR DPP10 HDAC6 LRP6 OR5D13 RELN TRIM24
ATRX DPPA4 HERC2 LRRC4C PABPC5 RET TRIM58
AURKC DSP HFM1 LRRK2 PALB2 RGS17 TRRAP
AXIN2 EGFR HIST1H1B LTBP1 PAPPA2 RHOA TTF1
B2M EIF3A HIST1H2BD MACC1 PBRM1 ROS1 UBE3A
BCL11A EIF4G1 HIST1H2BK MAGEL2 PCDH10 RUNX1T1 UBR5
BCL9 EP300 HIST1H4E MAP2 PCDH11X RXRA UGT2B7
BECN1 EPAS1 HNRNPA2B1 MAP3K7 PCDH15 SDHA USP9X
BIRC6 EPB41L3 HOXD10 MAPK1 PDGFRA SELP VCAN
BLM EPHA2 HRAS MAPK9 PEG3 SEMA5A WRN
BRAF EPHA3 HSPG2 MBD1 PEX11A SERPINB4 XPO1
BRCA2 EPHA7 HUWE1 MED1 PFKP SETBP1 ZBTB16
BRIP1 ERBB2 IFNGR1 MED12 PIK3CA SIN3A ZIC1
BRWD3 ERBB4 IGF1R MET PIK3CG SIRT1 ZNF737
C6 ETV6 IL1RAPL1 MME PIK3R1 SIRT3 ZNF750
C9ORF135 EYA1 IL6ST MS4A14 PIWIL1 SLC26A7 ZNF804B
CASP8 EZH2 INPP5D MTOR PKD1 SLC9A1
CCND1 F13B INPPL1 MUC5B PKN1 SLIT2
CCNE1 F5 ITGB1 MUC6 PLCB1 SLITRK4
CD163 FAM101A JAK1 MYC PLEC SLX4
CD1E FAM155A JAK2 MYH1 PLSCR4 SMAD4
CDH1 FAM222B JAK3 MYH10 POM121L12 SMARCA2
CDH10 FANCA KCNT2 MYH11 POT1 SMARCA4
CDH11 FANCB KDM5B MYH9 PRDX4 SMO
CDH5 FANCC KDM6A NBN PRIM2 SORCS1
